Persistence of post-COVID lung parenchymal abnormalities during the three-month follow-up by Zubairi, Ali Bin Sarwar et al.
eCommons@AKU 
Section of Pulmonary & Critical Care Department of Medicine 
9-28-2021 
Persistence of post-COVID lung parenchymal abnormalities 
during the three-month follow-up 
Ali Bin Sarwar Zubairi 
Aga Khan University, ali.zubairi@aku.edu 
Anjiya Shaikh 
Aga Khan University, anjiya.shaikh@scholar.aku.edu 
Syed Muhammad Zubair 
Aga Khan University, syed.zubair@aku.edu 
Akbar Shoukat Ali 
Aga Khan University, akbar.shoukatali@aku.edu 
Safia Awan 
Aga Khan University, safia.awan@aku.edu 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare 
 Part of the Critical Care Commons, Pulmonology Commons, Respiratory Tract Diseases Commons, 
and the Virus Diseases Commons 
Recommended Citation 
Zubairi, A., Shaikh, A., Zubair, S. M., Ali, A. S., Awan, S., Irfan, M. (2021). Persistence of post-COVID lung 
parenchymal abnormalities during the three-month follow-up. Advances in Respiratory Medicine, 89(5), 
477-483. 
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare/174 
Authors 
Ali Bin Sarwar Zubairi, Anjiya Shaikh, Syed Muhammad Zubair, Akbar Shoukat Ali, Safia Awan, and 
Muhammad Irfan 
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare/174 
ORIGINAL RESEARCH
477www.journals.viamedica.pl
Address for correspondence: Ali Bin Sarwar Zubairi, Section of Adult Infectious Diseases, Department of Medicine, Aga Khan University, Karachi, Pakistan; e-mail: ali.zubairi@aku.edu
DOI: 10.5603/ARM.a2021.0090  |  Received: 08.03.2021  |  Copyright © 2021 PTChP  |  ISSN 2451–4934  |  e-ISSN 2543–6031
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as 
long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Ali Bin Sarwar Zubairi1, Anjiya Shaikh2, Syed Muhammad Zubair1, Akbar Shoukat Ali1, 
Safia Awan1, Muhammad Irfan1
1Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan
2Medical College, Aga Khan University, Karachi, Pakistan
Persistence of post-COVID lung parenchymal abnormalities 
during the three-month follow-up
Abstract
Introduction: COVID-19-associated pulmonary sequalae have been increasingly reported after recovery from acute infection. 
Therefore, we aim to explore the charactersitics of persistent lung parenchymal abnormalities in patients with COVID-19.
Material and methods: An observational study was conducted in patients with post-COVID lung parenchymal abnormalities 
from April till September 2020. Patients ≥18 years of age with COVID-19 who were diagnosed as post-COVID lung parenchymal 
abnormality based on respiratory symptoms and HRCT chest imaging after the recovery of acute infection. Data was recorded on 
a structured pro forma, and descriptive analysis was performed using Stata version 12.1.
Results: A total of 30 patients with post-COVID lung parenchymal abnormalities were identified. The mean age of patients was 
59.1 (SD 12.6), and 27 (90.0%) were males. Four HRCT patterns of lung parenchymal abnormalities were seen; organizing pneu-
monia in 10 (33.3%), nonspecific interstitial pneumonitis in 17 (56.7%), usual interstitial pneumonitis in 12 (40.0%) and probable 
usual interstitial pneumonitis in 14 (46.7%). Diffuse involvement was found in 15 (50.0%) patients, while peripheral predominance 
in 15 (50.0%), and other significant findings were seen in 8 (26.7%) patients. All individuals were treated with corticosteroids. The 
case fatality rate was 16.7%. Amongst the survivors, 32.0% recovered completely, 36.0% improved, while 32.0% of the patients 
had static or progressive disease.
Conclusion: This is the first study from Southeast Asia that identified post-COVID lung parenchymal abnormalities in patients 
who had no pre-existing lung disease highlighting the importance of timely recognition and treatment of this entity that might 
lead to fatal outcome. 
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Introduction
The coronavirus disease 2019 (COVID-19) 
caused by the novel coronavirus severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2) 
has posed a global economic, psychosocial, 
political and medical challenge. As patients re-
cover from COVID-19 disease, we are approach-
ing an era where physicians would encounter 
COVID-19-associated pulmonary sequelae. These 
could be infectious, like COVID-19-associated 
pulmonary aspergillosis (CAPA) [1]; or noninfec-
tious which could include COVID-19-associated 
interstitial lung disease (ILD). The previous epi-
demics of coronavirus due to severe acute respi-
ratory distress syndrome coronavirus (SARS-CoV) 
and middle east respiratory syndrome coronavi-
rus (MERS-CoV) also led to the development of 
pulmonary fibrosis [2, 3].
ILD covers a wide spectrum of pulmonary pa-
renchymal disorders of both known and unknown 
etiology. Different radiological and histopatholog-
ic patterns of ILD have been described, some of 
them include usual interstitial pneumonitis (UIP), 
nonspecific interstitial pneumonitis (NSIP), and 
organizing pneumonia (OP) [4]. Similar patterns 
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can also occur as a result of pulmonary infections, 
like pneumocystis pneumonia or cytomegalovirus 
pneumonitis [5, 6].
The precise diagnosis of lung parenchymal ab-
normalities during COVID-19 pandemic remains 
challenging, mainly because invasive testing like 
bronchoscopies, open lung biopsies or autopsies 
are rarely performed in COVID-19 patients due 
to risk of disease transmission. Although there 
are multiple reports on the importance of CT in 
diagnosing COVID-19 infection, there is little or no 
data on the clinical presentation and management 
of patients with post-COVID lung parenchymal 
abnormalities. Myall et al. described the cohort of 
pateints with persistent inflammatory interstitial 
lung disease with remarkable improvement on 
early initiation of steroids [7]. The rationale of 
the study was that certain patients after recovery 
from COVID-19 infection might present with new, 
persistent or worsening respiratory symptoms due 
to long-term COVID-19-associated pulmonary se-
quelae which are usually underdiagnosed. Hence 
via this study, we aim to emphasize that diagnos-
ing post-COVID lung parenchymal abnormalities 
with proper follow-up is of utmost importance so 
that early and proper management can be facili-
tated and fatal outcomes can be prevented.
Material and methods
Ethical approval
Approval of the Ethical Review Committee 
(ERC) of the Aga Khan University Hospital located 
in Karachi, Pakistan was obtained.
Study design and setting
This single-center observational study was 
performed between April 1, 2020 and September 
15, 2020 at the Aga Khan University Hospital, 
the largest tertiary care center located in Kara-
chi, Pakistan. We retrospectively collected the 
demographic, clinical, laboratory and radiologi-
cal data of patients presenting with post-COVID 
lung parenchymal abnormalities from medi-
cal records. Disease severity of patients with 
COVID-19 infection was classified according to 
the WHO classification [8]. High- resolution com-
puted tomography (HRCT) of the chest findings, 
treatment and outcomes were recorded.
Study subjects
Patients who were seen in the outpatient Pul-
monology clinic or inpatient consultation service 
at the Aga Khan University Hospital owing to 
persistent respiratory symptoms after recovery 
from COVID-19 infection were included in the 
study. Follow-up imaging was performed 8 to 
12 weeks after recovery from acute infection and 
was compared with previous imaging for disease 
progression, improvement or resolution. 
Identification of post-COVID lung 
parenchymal abnormality
The identification of post-COVID lung paren-
chymal abnormality in our study was based on 
“new, persistent and/or worsening of respiratory 
symptoms and identification of lung parenchy-
mal abnormality pattern on HRCT imaging of 
the chest after the initial recovery phase of acute 
COVID-19 infection defined as 8 to 12 weeks after 
the onset of infection with no previous history of 
lung disease. They were identified by specialists 
in ILD clinic or on inpatient consultation”.
Inclusion and exclusion criteria
Adult patients (aged 18 and above) who were 
confirmed for SARS-CoV-2 by nasopharyngeal 
and/or oropharyngeal swabs for real-time RT-PCR 
at initial presentation and underwent chest imag-
ing on subsequent follow-up visits were included 
in our study. The patients with pre-existing lung 
disease and those with incomplete medical re-
cords were excluded.
Operational definition of outcomes
We have defined outcomes as complete re-
covery, improvement and progression of the 
disease process. The patients were labelled as 
completely recovered if they returned to their 
baseline functional status and chest imaging 
showed complete clearance of lung infiltrates 
after the identification of post-COVID lung paren-
chymal abnormalities. Improvement was defined 
as subjective improvement in functional status 
but not to the baseline and at least 50% clearance 
of radiological infiltrates. The patients whose 
symptoms persisted with interval worsening of 
functional status and no significant improvement 
or worsening of lung infiltrates were defined as 
progression of the disease process. 
HRCT chest analysis
The key HRCT chest findings of post-COVID 
lung parenchymal abnormalities were defined us-
ing standard taxonomy described in the literature 
with interstitial patterns including but not limited 
to diffuse ground-glass opacities with or without 
traction bronchiectasis (NSIP), basal and periph-
eral reticular opacities with honey combing (UIP) 
and peripheral and peribronchovascular consol-
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idation with or without ground-glass opacities 
(OP) [9]. The main HRCT findings were described 
as ground-glass opacities (GGO), consolidation, 
honeycombing/fibrosis and interlobular septal 
thickening/reticulation. Other HRCT findings 
included crazy paving, reverse halo sign, traction 
bronchiectasis and emphysematous cysts. The 
distribution of pulmonary involvement was re-
ported as either peripheral or diffuse.
Statistical analysis
Statistical analyses were performed using 
STATA version 12.1 (StataCorp LLC, College 
Station, Texas, USA). Quantitative data were 
presented as mean ± standard deviation (SD) or 
as median with inter-quartile range (IQR), while 
percentages of the total, unless stated otherwise, 
were used to represent qualitative (categorical) 
data.
Results
As shown in Table 1, our cohort included 
30 patients, 27 were males (90.0%) with an av-
erage age of 59.14 ± 12.60. Common presenting 
symptoms of COVID-19 disease were fever (30, 
100.0%), cough (19, 63.3%) and shortness of 
breath (23, 76.7%). During initial COVID-19 dis-
ease, 16 (53.3%) patients had severe disease and 
14 (46.7%) had critically ill disease. All individuals 
required supplemental oxygen. Out of 14 critically 
ill patients, 12 (85.7%) were treated with non-in-
vasive ventilation (NIV) and 2 (14.3%) patients 
were treated with invasive mechanical ventilation.
All patients in our cohort were found to have 
bilateral lung disease. Four HRCT patterns of lung 
parenchymal abnormalities were seen (Table 2). 
Diffuse involvement was found in 15 (50.0%) 
patients, while peripheral predominance in 
15 (50.0%) and other significant findings were 
seen in 8 (26.7%) study subjects.
All patients were treated with corticosteroids 
(0.5–1 mg/kg/day) for average duration of 8 to 
12 weeks. Two individuals were treated with pir-
fenidone for fibrotic lung disease. Home oxygen 
was needed in 28 (93.3%) patients.
Table 1. Clinical and demographic characteristics of pa-
tients with post-COVID lung parenchymal abnor-
malities (n = 30)
Variables Findings
Age [years], mean ± SD 59.1 ± 12.6
Gender, n (%)
   Male




   Diabetes mellitus
   Hypertension
   Chronic obstructive pulmonary disease
   Chronic liver disease 
   Malignancy
   Ischemic heart disease
   Inflammatory bowel disease










   Current smokers
   Ex-smokers 




Symptoms on presentation with COVID-19, n (%)
   Fever
   Shortness of breath
   Cough
   Fatigue






Persistent  respiratory symptoms, n (%)
   Persistent cough
   Persistent shortness of breath
13 (43.3)
29 (96.7)
Severity of COVID-19 Disease on initial presentation, n (%)
   Non-severe
   Severe




Treatment given for post-COVID lung parenchymal 
abnormalities, n (%) 
   Home oxygen
   Prednisolone




COVID-19 — coronavirus disease 2019; SD — standard deviation
Table 2. Radiological patterns of post-COVID lung paren-
chymal abnormalities (n = 30)
Variables Findings
Main findings, n (%)
   Patchy consolidation with ground glass 
   opacity (OP pattern)
   Diffuse ground glass opacities 
   (NSIP pattern)
   Honeycombing/Fibrosis (UIP pattern)
   Interlobular Septal Thickening/Reticulation 






   Peripheral 
   Diffuse
15 (50.0)
15 (50.0)
Other findings, n (%)
   Crazy paving
   Reverse halo sign
   Traction bronchiectasis





COVID-19 — coronavirus disease 2019; OP — organizing pneumonia; NSIP — 
nonspecific interstitial pneumonia; UIP — usual interstitial pneumonia
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A total of eight subjects had pulmonary func-
tions test (PFT). Median and IQR of forced vital 
capacity (FVC) was 92.5% (43.2%–102.7%). Four 
patients had normal pulmonary functions. How-
ever, three persons had reduced FVC. Diffusion 
capacity of the lungs for carbon monoxide (DLCO) 
was done in three cases, out of which two patients 
had moderately reduced and one individual had 
normal DLCO.
Five patients died during the disease course; 
4 (80.0%) patients died due to hypoxic respiratory 
failure, while 1 (20.0%) succumbed to superim-
posed aspergillus infection. Majority of the study 
subjects who died; 3 (60.0%), had progressive 
disease with UIP pattern. The CT images of 3 pa-
tients with different patterns of lung parenchymal 
abnormalities are shown in Figure 1–3. Out of the 
25 alive patients, 8 (32.0%) recovered completely, 
9 (36.0%) improved, while 8 (32.0%) patients had 
static or progressive disease.
Discussion
Our study found four distinct lung parenchy-
mal abnormalities associated with COVID-19 dis-
ease. Development of lung parenchymal abnor-
malities amongst survivors of COVID-19 disease 
has been reported during the ongoing pandemic, 
however, data is limited to case reports [10–12]. 
Literature from the previous outbreaks of viral 
infections such as SARS and MERS, in 2002 and 
2012 respectively, reported that clinico-radiologi-
cal changes persisted in approximately one-third 
of patients even after 12 weeks of discharge [2, 3].
The majority of our patients who developed 
lung parenchymal abnormalities were males, which 
is reported in literature with certain ILDs-like idio-
pathic pulmonary fibrosis [13, 14]. COVID-19-as-
sociated fibrosis is one of the lung insults already 
described with previous coronavirus infections 
[2, 3], and there are emerging studies now reporting 
COVID-19- associated early pulmonary fibrosis. In 
the initial papers, Pan et al. and Zhou et al. re-
ported fibrotic changes in the imaging features of 
patients with COVID-19 pneumonia [15, 16]. Since 
then, fibrotic lung parenchymal remodelling [17, 
18], fibrosing diffuse alveolar damage (DAD) [19] 
and honeycombing [20] have also been confirmed 
after invasive testing such as cryobiopsies and au-
topsies in smaller cohorts. Li Yan et al. described 
DAD on autopsy of 30 patients with COVID-19, 
showing 43% developing fibrosing patterns while 
25% showing organizing pattern [19].
Post-infectious secondary OP is also a known 
entity, well described with certain viruses like 
Cytomegalovirus and Influenza-A (H1N1) [6, 
21]. Pathology in patients who recovered from 
SARS-CoV has shown fibrogranulation tissue 
proliferation and organizing pneumonia-like 
patterns [22] while MERS-associated organizing 
pneumonia has also been documented [23, 24]. 
Studies of COVID-19 CT imaging, coupled with 
postmortem lung biopsies and autopsies during 
the ongoing pandemic, suggest the development 
of a secondary OP, which at present remains an 
underrecognized complication [25]. 
A distinct feature of organizing pneumonia 
and NSIP is the resolution with corticosteroid 
treatment. Although the use of corticosteroids 
has been recommended in the treatment of 
COVID-19 disease [26[, there is limited data on 
response of prolonged or higher dose corticoste-
Figure 1. HRCT of the chest  showing A. ground glass opacities (GGOs) and interlobular septal thickening (yellow arrow showing GGOs and septal 
thickening); and B. interval reduction in GGOs and septal thickeneing after initiation of corticosteroids
A B
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roids in post-COVID lung parenchymal abnormal-
ities. Myall et al. described the cohort of pateints 
in which thirty individuals with post-COVID 
organising pneumonia pattern were treated with 
corticosteroids with significant improvement [7].
In our cohort, most patients developed a pre-
dominant OP or NSIP pattern with severe to 
critically ill disease. Most persons with an OP 
and NSIP pattern improved significantly with 
steroids, showing both clinical and radiological 
improvement. The patients showing UIP pattern, 
however, largerly remained static or progressed. 
Majority of the deaths in our cohort were in the 
patients showing UIP pattern.
Disease severity did not seem to have a sig-
nificant impact on development of any particular 
pattern of lung parenchymal abnormality. This 
proves that these reported lung microstructure 
changes are not only a result of post-ARDS fibro-
sis or ventilator-induced lung damage, but also 
a consequence of the direct virus-induced injury 
and aberrant local immune response leading to 
lung parenchymal abnormalities. Combet et al. re-
cently described a case of a spontaneously breath-
ing patient who developed rapid honeycombing 
following COVID-19 disease which responded to 
high-dose steroids and nintedanib [27]. Tale et 
al. also reported a similar case of a patient with 
Figure 2. HRCT of the chest of showing A. peripheral patchy areas ground glass opacities (GGOs) with consolidation consistent with an OP (organi-
zing pneumonia) pattern (yellow arrow pointing towards peripheral patchy GGOs); and B. near complete resolution of peripheral patchy consolidation 
after initiation of corticosteroids
A B
Figure 3. HRCT of the chest showing A. honeycombing and reticulation (yellow arrow showing honeycombing); and B. persistent and worsening 
of honeycomb fibrosis (yellow arrow showing honeycombing)
A B
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persistent hypoxemia after recovery from mod-
erate COVID-19 disease with 3-week follow-up 
HRCT showing artitechtural distortion, interlobar 
septal thickening and traction bronchiectasis 
[28]. These case reports reiterate our stance that 
predisposed patients who are moderately ill, and 
do not require mechanical ventilation can also 
develop early fibrotic changes. However, study 
conducted by Han et al. had findings contrary to 
that of ours. They extrapolated that in patients 
with age greater than 50, increased heart rate 
on admission, increased duration of hospital 
stay, non-invasive mechanical ventilation and 
extensive CT involvement at initial CT were risk 
factors for fibrotic changes at 6-month follow-up 
[29]. Post-viral pulmonary fibrosis associated 
with previous coronaviruses has been seen in 
patients with critical disease leading to ARDS 
with longer duration of illness requiring ICU stay 
and invasive mechanical ventilation [2]. Howev-
er, SARS-CoV-2 has shown to induce fibrosis in 
patients who did not require invasive mechanical 
ventilation or ICU stay in our study. 
To the best of our knowledge, this is a first 
case series emphasizing and presenting data of 
30 patients with different patterns of post-COVID 
lung parenchymal abnormalities along with their 
follow-up from a low to middle income country.
Our study has several limitations which in-
clude, among others, the absence of histopatho-
logic confirmation of lung parenchymal abnor-
malities. Transbronchial and open lung biopsies 
were not performed due to the cost, invasive 
nature of procedure and risk of transmission of 
COVID-19; therefore, our patients were diagnosed 
solely on clinical and radiological grounds. A lim-
ited number of PFTs and DLCO were performed to 
assess the physiologic function.
Conclusion
Post-COVID lung parenchymal abnormalities 
are an increasingly recognized clinical entity. 
A close follow-up is essential in these patients, 
as they may require prolonged treatment with 
corticosteroids in relatively higher doses. The 
long-term effects of post-COVID lung sequelae 
are yet to be determined, and a longitudinal fol-
low-up will help us further explore the nature of 
the disease.
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